Filgrastim Efficiency in Cats Naturally Infected with Feline Panleukopenia Virus

Overview

Journal Animals (Basel)

Date 2025 Jan 8

PMID 39765486

Authors

Mihaela Anca Dascalu

Florentina Daraban Bocaneti

Octavian Soreanu

Paul Tutu

Andreea Cozma

Serban Morosan

Oana Tanase

Affiliations

Soon will be listed here.

Abstract

Feline Panleukopenia (FPL) infection is caused by feline panleukopenia virus (FPV), and it is considered one of the most severe cat's infectious diseases. Since there is no specific antiviral treatment for FPL, the therapeutic protocol usually is focused on fluid therapy and supportive care. However, filgrastim, a granulocyte colony-stimulating factor (G-CSF) used in human medicine to treat neutropenia and leukopenia, has been lately used in treating FPV disease, providing promising results. During January 2022 and September 2024, twenty-two cats diagnosed with feline panleukopenia virus were subjected to filgrastim (Zarzio, Sandoz, Kundl, Austria) administration at a dose of 6 µg/kg for 3 consecutive days. The 4th day was a break day, and in the 5th day, the complete blood count was repeated. White blood cells, lymphocytes, monocytes, neutrophils and eosinophils parameters improved after Zarzio administration, with a significant statistical difference ( < 0.01) when their values between day 1 (pre Zarzio administration) and day 5 (post Zarzio administration) were analysed. However, red blood cells, haemoglobin, haematocrit and platelets parameters registered a considerable reduction from day 1 to day 5 with a significant statistical difference ( < 0.01), considered as post-administration side effects. In our study, the survival rate following Zarzio administration was 100%, suggesting that the protocol involving three doses is effective in restoring the leukopenia and neutropenia.

References

Kailasan S, Agbandje-Mckenna M, Parrish C . Parvovirus Family Conundrum: What Makes a Killer?. Annu Rev Virol. 2016; 2(1):425-50. DOI: 10.1146/annurev-virology-100114-055150. View

Kruse B, Unterer S, Horlacher K, Sauter-Louis C, Hartmann K . Prognostic factors in cats with feline panleukopenia. J Vet Intern Med. 2010; 24(6):1271-6. DOI: 10.1111/j.1939-1676.2010.0604.x. View

Straka C, Oduncu F, Hinke A, Einsele H, Drexler E, Schnabel B . Responsiveness to G-CSF before leukopenia predicts defense to infection in high-dose chemotherapy recipients. Blood. 2004; 104(7):1989-94. DOI: 10.1182/blood-2004-02-0628. View

Minelli O, Falzetti F, Di Ianni M, Onorato M, Plebani S, Silvani C . G-CSF-induced thrombocytopenia in a healthy donor. Bone Marrow Transplant. 2008; 43(3):263-4. DOI: 10.1038/bmt.2008.310. View

Furlow B . G-CSF could worsen anaemia in breast cancer. Lancet Oncol. 2006; 7(8):622. DOI: 10.1016/s1470-2045(06)70778-1. View

Mishu L, CALLAHAN G, Allebban Z, Maddux J, Boone T, Souza L . Effects of recombinant canine granulocyte colony-stimulating factor on white blood cell production in clinically normal and neutropenic dogs. J Am Vet Med Assoc. 1992; 200(12):1957-64. View

Li Y, Guo R, Wang L, Li S, Zhu Z, Tu P . G-CSF administration results in thrombocytopenia by inhibiting the differentiation of hematopoietic progenitors into megakaryocytes. Biochem Pharmacol. 2019; 169:113624. DOI: 10.1016/j.bcp.2019.113624. View

Shao T, Hsu R, Rafizadeh D, Wang L, Bowlus C, Kumar N . The gut ecosystem and immune tolerance. J Autoimmun. 2023; 141:103114. DOI: 10.1016/j.jaut.2023.103114. View

Ferri F, Porporato F, Rossi F, Enache D, Callegari C, Gerardi G . Treatment with Class A CpG Oligodeoxynucleotides in Cats with Naturally Occurring Feline Parvovirus Infection: A Prospective Study. Viruses. 2020; 12(6). PMC: 7354499. DOI: 10.3390/v12060640. View

10.

Fernandez-Varon E, Villamayor L . Granulocyte and granulocyte macrophage colony-stimulating factors as therapy in human and veterinary medicine. Vet J. 2006; 174(1):33-41. DOI: 10.1016/j.tvjl.2006.08.001. View

11.

Lanevschi A, Daminet S, Niemeyer G, Lothrop Jr C . Granulocyte colony-stimulating factor deficiency in a rottweiler with chronic idiopathic neutropenia. J Vet Intern Med. 1999; 13(1):72-5. View

12.

McKenzie E, Tornquist S, Gorman M, Cebra C, Payton M . Hematologic effects of subcutaneous administration of recombinant human granulocyte colony-stimulating factor (filgrastim) in healthy alpacas. Am J Vet Res. 2008; 69(6):770-6. DOI: 10.2460/ajvr.69.6.770. View

13.

Chanachaivirada R, Chuammitri P, Lampa K, Prachasilchai W, Sodarat C . Therapeutic Effects of and Lipopolysaccharide from in Cats with Feline Panleukopenia. Vet Sci. 2024; 11(6). PMC: 11209590. DOI: 10.3390/vetsci11060253. View

14.

Addie D, Toth S, Thompson H, Greenwood N, Jarrett J . Detection of feline parvovirus in dying pedigree kittens. Vet Rec. 1998; 142(14):353-6. DOI: 10.1136/vr.142.14.353. View

15.

Mischke R, Barth T, Wohlsein P, Rohn K, Nolte I . Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on leukocyte count and survival rate of dogs with parvoviral enteritis. Res Vet Sci. 2001; 70(3):221-5. DOI: 10.1053/rvsc.2001.0464. View

16.

Awad R, Khalil W, Attallah A . Epidemiology and diagnosis of feline panleukopenia virus in Egypt: Clinical and molecular diagnosis in cats. Vet World. 2018; 11(5):578-584. PMC: 5993757. DOI: 10.14202/vetworld.2018.578-584. View

17.

Fulton R, Gasper P, Ogilvie G, Boone T, Dornsife R . Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis in normal cats. Exp Hematol. 1991; 19(8):759-67. View

18.

Kim K, An J, Lee J, Park S, Chae H, Song W . Transient thrombocytopenia in a cat following G-CSF treatment. Vet Med Sci. 2021; 8(2):421-424. PMC: 8959317. DOI: 10.1002/vms3.706. View

19.

Truyen U, Addie D, Belak S, Boucraut-Baralon C, Egberink H, Frymus T . Feline panleukopenia. ABCD guidelines on prevention and management. J Feline Med Surg. 2009; 11(7):538-46. PMC: 7129762. DOI: 10.1016/j.jfms.2009.05.002. View

20.

Zinkl J, Madigan J, Fridmann D, Kabbur M, Andresen J . Haematological, bone marrow and clinical chemical changes in neonatal foals given canine recombinant granulocyte-colony stimulating factor. Equine Vet J. 1994; 26(4):313-8. DOI: 10.1111/j.2042-3306.1994.tb04392.x. View